About: Elesclomol

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Elesclomol Goto Sponge NotDistinct Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/c/3Gkm7QzUkg

Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. Synta Pharmaceuticals announced on February 26, 2009 the suspension of all clinical trials involving Elesclomol due to safety concerns. In March 2010, Synta announced that the FDA had approved resuming clinical development of elesclomol, and that they expected to initiate one or more clinical trials for elesclomol in the second half of the year.

Attributes	Values
rdf:type	Thing dul:ChemicalObject chemical substance Drug yago:WikicatChemotherapeuticAdjuvants yago:WikicatOrphanDrugs yago:Addition102679415 yago:Additive102679788 yago:Adjuvant102680947 yago:Agent114778436 yago:CausalAgent100007347 yago:Component103081021 yago:Drug103247620 yago:Matter100020827 yago:Object100002684 yago:Part103892891 yago:PhysicalEntity100001930 drug yago:Substance100020090 umbel-rc:DrugProduct
rdfs:label	Elesclomol (en)
rdfs:comment	Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. Synta Pharmaceuticals announced on February 26, 2009 the suspension of all clinical trials involving Elesclomol due to safety concerns. In March 2010, Synta announced that the FDA had approved resuming clinical development of elesclomol, and that they expected to initiate one or more clinical trials for elesclomol in the second half of the year. (en)
foaf:depiction
dcterms:subject	Hydrazides Chemotherapeutic adjuvants Orphan drugs
Wikipage page ID	20362616 (xsd:integer)
Wikipage revision ID	1065089733 (xsd:integer)
Link from a Wikipage to another Wikipage	Cancer FDA Fast Track Development Program Hydrazides Melanoma Orphan drug GlaxoSmithKline Apoptosis Statistical significance Clinical trial Progression-free survival Chemotherapeutic adjuvants U.S. Food and Drug Administration Orphan drugs dbr:Paclitaxel Randomized controlled trial International Nonproprietary Name Metastasis Reactive oxygen species Oxidative stress Chemotherapy adjuvant dbr:Synta_Pharmaceuticals
sameAs	Elesclomol Elesclomol Elesclomol Elesclomol Elesclomol Elesclomol Elesclomol
dbp:wikiPageUsesTemplate	dbt:Chemotherapeutic_agents dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite
thumbnail	wiki-commons:Special:FilePath/Elesclomol.svg?width=300
alt	Skeletal formula (en) Space-filling model (en)
ATC prefix	none (en)
c	19 (xsd:integer)
CAS number	488832 (xsd:integer)
ChEBI	79369 (xsd:integer)
ChEMBL	1972860 (xsd:integer)
ChemSpiderID	265501 (xsd:integer)
DrugBank	DB05719 (en)
H	20 (xsd:integer)
image	Elesclomol-3D-spacefill.png (en)
IUPAC name	N′1,N′3-dimethyl-N′1,N′3- bispropanedihydrazide (en)
KEGG	D08909 (en)
n	4 (xsd:integer)
O	2 (xsd:integer)
PubChem	300471 (xsd:integer)
s	2 (xsd:integer)
StdInChI	1 (xsd:integer)
StdInChIKey	BKJIXTWSNXCKJH-UHFFFAOYSA-N (en)
UNII	6 (xsd:integer)
Verifiedfields	changed (en)
verifiedrevid	446146469 (xsd:integer)
Watchedfields	changed (en)
width	250 (xsd:integer)
has abstract	Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. Synta Pharmaceuticals announced on February 26, 2009 the suspension of all clinical trials involving Elesclomol due to safety concerns. In March 2010, Synta announced that the FDA had approved resuming clinical development of elesclomol, and that they expected to initiate one or more clinical trials for elesclomol in the second half of the year. In a small, randomized phase II study, elesclomol was shown to significantly increase progression-free survival in people with metastatic melanoma when given in addition to paclitaxel (Taxol). Results from a phase III trial were announced in March 2013. The study was halted when it was determined that addition of elesclomol to paclitaxel didn't significantly increase progression-free survival. Studies in preclinical models suggested that Elesclomol may be effective in Ewing sarcoma cells with elevated levels of cellular oxidative stress. (en)
gold:hypernym	Drug
prov:wasDerivedFrom	wikipedia-en:Elesclomol?oldid=1065089733&ns=0
page length (characters) of wiki page	8306 (xsd:nonNegativeInteger)
CAS number	488832-69-5
ChEBI	79369
ChEMBL	1972860
DrugBank	DB05719

Faceted Search & Find service v1.17_git147 as of Sep 06 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3332 as of Dec 5 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 59 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software